Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 7/20 | 0.52 |
| ▸ | MMP8 | P22894 | 7/20 | 0.52 |
| ▸ | MMP1 | P03956 | 4/20 | 0.52 |
| ▸ | MMP3 | P08254 | 2/20 | 0.52 |
| ▸ | IL1RN | P18510 | 3/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | GHSR | Q92847 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8418339 | 1.00 | MMP9 (0.52) | MMP9MMP8MMP1MMP3IL1RN | |
| SCHEMBL8227146 | 0.90 | MEN1 (0.53) | MMP9MMP8MMP1MMP3MMP2 | |
| SCHEMBL8229466 | 0.90 | MEN1 (0.53) | MMP9MMP8MMP1MMP3MMP2 | |
| SCHEMBL8221846 | 0.90 | MEN1 (0.53) | MMP9MMP8MMP1MMP3MMP2 | |
| SCHEMBL8221855 | 0.90 | MEN1 (0.53) | MMP9MMP8MMP1MMP3MMP2 | |
| SCHEMBL8420523 | 0.88 | MEN1 (0.51) | MMP9MMP8MMP1MMP3MMP2 | |
| SCHEMBL14446363 | 0.88 | GHSR (0.53) | MMP9MMP8MMP1MMP3IL1RN | |
| SCHEMBL14446439 | 0.88 | GHSR (0.53) | MMP9MMP8MMP1MMP3IL1RN | |
| SCHEMBL14446443 | 0.88 | GHSR (0.53) | MMP9MMP8MMP1MMP3IL1RN | |
| SCHEMBL14446366 | 0.88 | GHSR (0.53) | MMP9MMP8MMP1MMP3IL1RN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335726-B2 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | CUBIST PHARMACEUTICALS, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223983-A1 | Lipopeptide stereoisomers, methods for preparing same and useful intermediates | NGLY1, LSS, NRDC | MMP9 2746/4885MMP8 453/4885MMP1 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.